Myfreesia (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol and Levonorgestrel, the active ingredients in Myfreesia, are a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age.

GNH USA supplies Myfreesia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Myfreesia, a combined oral contraceptive, acts on the hormonal regulation of the menstrual cycle to prevent pregnancy.

Contraception: prevents unintended pregnancy in women of reproductive age. Menstrual cycle regulation: helps achieve more predictable bleeding patterns. Acne management: may improve hormonal acne associated with menstrual fluctuations.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: temporary swelling or discomfort. - Spotting or breakthrough bleeding: irregular light bleeding. - Weight gain: modest fluid retention. - Mood changes: irritability or mild depression.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Stroke or transient ischemic attack. - Myocardial infarction: heart attack risk, especially in smokers over 35. - Severe hypertension: sudden rise in blood pressure. - Liver tumor: benign hepatic adenoma. - Allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Myfreesia, clinicians should assess individual risk factors and counsel patients on proper use. - Cardiovascular risk assessment: evaluate history of clotting disorders, hypertension, or smoking. - Liver function review: avoid use in severe hepatic impairment. - Smoking status: contraindicated in women over 35 who smoke. - Drug interaction check: review concurrent medications that may reduce efficacy. - Missed pill guidance: provide clear instructions for managing skipped doses. - Store at below 25°C: keep in the original pack, protect from moisture.

Myfreesia can interact with several medicines that alter hormone metabolism or affect clotting risk.

Major Interactions (Avoid): - Rifampin: induces hepatic enzymes, reducing contraceptive effectiveness. - Phenytoin: enzyme inducer that may lower hormone levels. - Efavirenz: antiretroviral that decreases plasma concentrations. - St. John’s wort: herbal inducer leading to reduced efficacy. - Ketoconazole: potent CYP3A4 inhibitor, may increase hormone exposure.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine): may increase bleeding tendency. - Diuretics: can affect electrolyte balance and blood pressure. - Antihypertensives (e.g., ACE inhibitors): monitor blood pressure changes. - Digoxin: possible alteration in serum levels. - Fluconazole: moderate CYP3A4 inhibition, may raise hormone levels.